

Financial Disclosures

The CONy Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of CONy participants. In doing so, the CONy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The CONy Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflicts of interest is used for those members who do have financial interests related to the development of the content. Program members who fail to provide financial disclosures are not permitted to participate in the development of educational content.

Committee & Faculty

The CONy Congress considers financial relationships to create actual conflicts of interest when Committee & Faculty or their immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Committee & Faculty) have both a financial relationship with a commercial interest and the opportunity to affect the policy of the CONy Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias.

All Committee & Faculty of CME content should familiarize themselves with the policy of the CONy Congress of CME based on the CME provider of the Congress – the EACCME (<http://admin.uems.net/uploadedfiles/174.pdf>).

All CONy Faculty presenting CME are required to disclose to the activity audience the following information prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services within the past 12 months. The CONy Congress defines "relevant" financial relationships as those with a commercial ophthalmic interest and the opportunity to affect the content of CME about the products or services of that commercial ophthalmic interest
- CME Committee & Faculty who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

NOTE: All Committee & Faculty are required to report financial disclosures, using the codes below. An individual's financial disclosures for the 10th CONy Congress meeting are listed in this Section.

CONy Financial Disclosure Codes

Category	Code	Description
None	N	No financial relationships
Advisory Board	B	Member of a company advisory board, board of directors or other similar group
Lecture fees	L	Lecture fees, consultant fees, honoraria, travel fees or reimbursements when speaking at the invitation of a commercial entity for the past 1 year
Sponsored	S	Participation in a company sponsored speakers' bureau
Equity owner	O	Equity ownership/stock options
Grant support	G	Grant support, research support for the past 1 year (all sources) and all sources used for this project

Disclosure Information

Financial interest disclosures from program members and others in a position for content control

Aida Abu-Baker, Canada No conflicts	N	Anca Dana Buzoianu, Romania <i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>	
Frank Andrasik, USA No conflicts	N	Jorge Campos, Portugal No conflicts	N
Ovidiu Bajenaru, Romania Abbvie AOP Orphan Astra-Zeneka Biogen Boehringer-Ingelheim Teva UCB	L L G, L G L L L	Louis Caplan, USA No conflicts	N
Stavros Baloyannis, Greece No conflicts	N	Rudolph Castellani, USA No conflicts	N
Elinor Ben Menachem, Sweden Bial Eisai UCB	G, L L L	Pedro Castro, Portugal No conflicts	N
Daniel Bereczki, Hungary Gideon Richter MSD Boehringer Ingelheim Teva	G L, S L, S S	Abhijit Chaudhuri, UK Biogen Novartis Terumo-BCT TEVA	L L L L
Heinrich Binder, Austria <i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>		João Chaves, Portugal Bial Eisai UCB	L, S S S
Ilan Blatt, Israel No conflicts	N	Michael Chopp, USA No conflicts	N
Sergiu Blumen, Israel No conflicts	N	Robert Cowan, USA Allergan Teva	G, L L
Julien Bogousslavsky, Switzerland No conflicts	N	Marinos Dalakas, Greece No conflicts	N
Hayrunnisa Bolay, Turkey No conflicts	N	Patrick Donohue, USA <i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>	
Ubaldo Bonuccelli, Italy Chiesi Italy Zambon Italia	G L	Vivian E. Drory, Israel No conflicts	N
Natan Bornstein, Israel No conflicts	N	Lars Edvinsson, Sweden No conflicts	N
Martin Brodie, UK Bial Eisai GSK GWPharmaceuticals Lundbeck UCB	L L, S L, S L L, S L, S	Cristian Falup-Pecurariu, Romania Bial Bristol-Myers Ipsen Lundbeck MDS Pfizer UCB	G L G G L L L
Roger Bullock, UK Axovant Lilly	L L	Ruggero G. Fariello, Italy Dexcell Pharma Zambon Spa, Italy	L L
		Alfonso Fassano, Canada MJ Fox Foundation University of Toronto Abbvie	G G L, S

Boston Scientific	L, S	Advanced Medical	L
Medtronic	L, S	Lewis Brisbois Bisgaard & Smith	L
Teva	L		
Novartis	L	Panteleimon Giannakopoulos, Switzerland	
UCB Pharma	L	No conflicts	N
Peter Feldschreiber, UK		Bruno Gran, UK	
No conflicts		Bayer Healthcare	G
Joaquim Ferreira, Portugal		Biogen	G, L
Abbott	L	Genzyme	G
Allergan	G	Merck	G, L
Bial	L, S	Novartis	G
Biogen	L, S	Roche	L
GSK	G, L	Teva UK	G, L
Grunenthal	G	Lea Grinberg, USA/Brazil	
Ipsen	L	AVID	G
Lundbeck	L	Elliott Gross, USA	
Merck-Serono	L	No conflicts	N
Merz	L	Alla Guekht, Russia	
MSD	G	No conflicts	N
MSD Portugal	G	Mark Hallett, USA	
Novartis	G, L	No conflicts	
Solvay	L	Hans Hamburger, The Netherlands	
Teva	G, L	No conflicts	N
José Ferro, Portugal		Hans-Peter Hartung, Germany	
Boehringer-Ingelheim	G, S	Biogen Idec	L
Daiichi	G	Genzyme	L
Lundbeck	G	F. Hoffmann-La Roche Ltd	L
Sankyo	G	MedImmune	L
Paulo Fontoura, Switzerland		Merck Serono	L
F. Hoffmann- La Roche Ltd	O	Novartis	L
<i>Employee</i>		Octapharm	L
Richard Frackowiak, Switzerland		Teva	L
Lippincott Woulters	L	Dieter Heiss, Germany	
Nestle	L	No conflicts	N
Roger de Spoelberch Foundation	L	Martin Holtkamp, Germany	
Mark Freedman, Canada		Cyberonics	L, S
Actelion	L, B	Eisai	L, S
Bayer Healthcare	L, B	Novartis	L, S
Biogen Idec	L, B	UCB	L, S
Chugai	L	Volker Hömberg, Germany	
EMD Canada	L	<i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>	
Genzyme	L, S	Zsolt Illes, Denmark	
Merck Serono	L, B	Biogen Idec	G, L, S
Novarits	L, B	Lundebeckfonden	G
Opexa	B	Novartis	L, S
Hoffmann-La Roche Ltd	L, B	Sanofi-Aventis-Genzyme	L, S
Sanofi-Aventis	L, B	Teva	L, S
Teva Canada Innovation	L	Ruth Itzhaki, UK	
Néstor Gálvez-Jiménez, USA		No conflicts	N
No conflicts	N	Kurt Jellinger, Austria	
Michael Geschwind, USA		No conflicts	N
NIH/NIA	G		
Quest Diagnostics	G		
Michael J. Homer Family Fund	G		
Cure PSP	G		
Tau Consortium	G		
MedaCorp	L		
Gerson-Lehman Group	L		
Best Doctors	L		

Eliezer Katz, USA MedImmune Employee	O	Lefkos Middleton, UK Astra Zeneca Janssen Pharmaceuticals Takeda UCB	G, L G L G
Miia Kivipelto, Sweden No conflicts	N	Ron Milo, Israel Bayer Biogen Idec Genzyme Merck Serono Neopharm Novartis Teva	G, L G, L, S L G, L L G, L, S G, L
Spiros Konitsiotis, Greece No conflicts	N	Dimos Mitsikostas, Greece Serono Bayer Genesis Bayer Genzyme Allergan Novartis Teva Brain Pharma	G G G L L L L L L
Amos D. Korczyn, Israel No conflicts	N	Jay P. Mohr, USA No conflicts	N
John Krakauer, USA No conflicts	N	Xavier Montalban, Spain Actelion Almirall Bayer Biogen Genzyme Merck Novartis Octapharma Receptos Roche Sanofi Teva Trophos	L L L L L L L L L L L L L
Jera Kruja, Albania Bayer Novartis	G G	Jose Monteiro, Portugal No conflicts	N
Jaime Kulisevsky, Spain No conflicts	N	Dafin Muresanu, Romania No conflicts	N
Jorge Miguel Lainez, Spain Amgen Allergan ATI Boehringer-Ingelheim Electrocore Lilly Novartis Otsuka Roche Teva	G G, L, S G, L G G L L G G L	Eduardo Nobile-Orazio, Italy Baxter, Italy and USA CSL Behring, Italy Grifols, Spain Kedrion, Italy LFB, France Novartis, Switzerland	L L L L, B G L, G
Jorge Lains, Portugal No conflicts	N	Michael O'Sullivan, UK No conflicts	
David Leppert, Switzerland Novartis Employee	O	Jose Obeso, Spain Boehringer-Ingelheim GSK, Spain Lundbeck, Spain USB, Spain Teva	L S S S L
Jerzy Leszek, Poland No conflicts	N		
Giancarlo Logroscino, Italy No conflicts	N		
Jacek Losy, Poland No conflicts	N		
Albert Ludolph, Germany No conflicts	N		
Sandra Macedo-Ribeiro, Portugal No conflicts	N		
Hugh Markus, UK No conflicts	N		
Dieter H. Meier, USA NeuroPore Therapies Employee	O		
Alexandre Mendonça, Portugal No conflicts	N		

Per Odin, Sweden		Abbvie	L, B
Abbvie	L	Bayer Healthcare	L, B
Brittania	L	Boehringer-Ingelheim	L, B
Nordie Infucare	L	Brittania	L, B
UCB	L	Cephalon	L, B
Zambon	L	Desitin	L, B
		GSK	L, B
C. Warren Olanow, USA		Lundbeck	L, B
<i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>		Medtronic	L, B
		Merck Serono	L, B
Victor Oliveira, Portugal		Novartis	L, B
No conflicts	N	Orion	L, B
		Pfizer	L, B
Tiago Fleming Outeiro, Germany		Teva	L, B
No conflicts	N	UCB	L, B
		Valeant	L, B
Cigdem Ozkara, Turkey		Zambon	L, B
No conflicts	N		
		Ivan Rektor, Czech Republic	
Sokratis Papageorgiou, Greece		No conflicts	N
No conflicts	N		
		Irena Rektorova, Czech Republic	
Andrew Papanicolaou, USA		No conflicts	N
No conflicts	N		
		Uroš Rot, Slovenia	
Laura Parkkinen, UK		Bayer	L
No conflicts	N	Biogen Idec	G, L
		Merck Serono	L
Friedemann Paul, Germany		Novartis	L
No conflicts	N	Teva	L
		Francisco Sales, Portugal	
Victor Pedro, USA		Bial	L, S
<i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>		Eisai	L, S
		UCB	L, S
Robert Perneckzy, UK			
No conflicts	N	Cristina Sampaio, USA	
		<i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>	
George Perry, USA			
No conflicts	N	Isabel Santana, Portugal	
		No conflicts	N
Victoria Popescu, Belgium			
Teva	L	João Sargento-Freitas, Portugal	
Genzyme	L	Bayer, Portugal	L
Icometrix	L	Boehringer-Ingelheim, Portugal	L
		Pfizer/Bristol Myers Squibb, Portugal	L
Martin Rabey, Israel			
<i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>		Angel Sesar, Spain	
		<i>Financial disclosures were not available prior to print, and will be announced at the start of the presentation</i>	
Alan Rapoport, USA			
Autonomic Technologies	L	Jack Schim, USA	
Avanir	L	Allergan	G, L, S
Depomed	L, S	Amgen	G
Doctor Reddy's	L	Boehringer-Ingelheim	L, S
Electrocore	L	Depomed	L, S
Impax	L	Lilly	G
Merck	L	Teva	G, L, S
Winston	L		
Teva	L, S	Robert Shapiro, USA	
		Lilly	L
Vered Raz, The Netherlands			
No conflicts		Noam Shemesh, Israel	
		No conflicts	N
Heinz Reichmann, Germany			
Abbott	L, B		

Stephen Silberstein, USA

Alder Biopharmaceuticals	L
Allergan	L
Amgen	L
Avanir	L
Curelator	L
Depomed	L
Dr. Reddy's	L
eNeura	L
Electrocore	L
Lilly	L
Supernus	L
Teva	L
Trigemina	L

Michael Sperling, USA

Accorda	G
Brain Sentinel	G
DARPA	G
Eisai	G
GSK	G
Marinus	G
Medtronic	G
NIH	G
SK Life Sciences	G
Sunovion	G
UCB	L
Upsher-Smith	G

Thorsten Steiner, Germany

Bayer	L
Boehringer-Ingelheim	L
Daiichi-Sankyo	L
Octapharma	G
Pfizer	L

Johnathan Streifler, Israel

No conflicts	N
--------------	---

Fabrizio Stocchi, Italy

Financial disclosures were not available prior to print, and will be announced at the start of the presentation

Olaf Stüve, USA

Genetech	L
Opexa Therapeutics	G
Sanofi Aventis	L
Teva	G

Ricardo Taipa, Portugal

No conflicts	N
--------------	---

William Theodore, USA

No conflicts	N
--------------	---

Babek Tousi, USA

ADRF	G
Avanir	G
Axovant	G
Biogen	G
Grifols	G
Lilly	L

Manjari Tripathi, India

No conflicts	N
--------------	---

Antonio Uccelli, Italy

Financial disclosures were not available prior to print, and will be announced at the start of the presentation

Antonio Vaz Carneiro, Portugal

No conflicts	N
--------------	---

Laszlo Vecsei, Hungary

Teva	L
Genzyme	L
Novartis	L
Biogen	L

Randall Weeks, USA

Depomed	G
---------	---

Brian Weinschenker, USA

Alexion	L
Chord	L
Chugai	L
MedImmune	L
Novartis	L